ReShape Lifesciences Inc. financial data

Symbol
RSLS on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
1001 Calle Amanecer, San Clemente, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
OBALON THERAPEUTICS INC (to 6/21/2021)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 212 % +16.8%
Quick Ratio 91.3 % +69.6%
Debt-to-equity 91.2 % +17.9%
Return On Assets -109 % +48.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.4M shares +751%
Common Stock, Shares, Outstanding 29.4M shares +751%
Entity Public Float 5.07M USD -52.4%
Common Stock, Value, Issued 29K USD +867%
Weighted Average Number of Shares Outstanding, Basic 25.2M shares +676%
Weighted Average Number of Shares Outstanding, Diluted 25.2M shares +676%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.05M USD -23%
Research and Development Expense 2.16M USD +4.09%
General and Administrative Expense 7.65M USD -47.8%
Operating Income (Loss) -10M USD +74%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -8.96M USD +74.6%
Income Tax Expense (Benefit) 63K USD +275%
Net Income (Loss) Attributable to Parent -9.02M USD +74.1%
Earnings Per Share, Basic 0.58 USD/shares +94.4%
Earnings Per Share, Diluted 0.58 USD/shares +94.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.05M USD -76.9%
Accounts Receivable, after Allowance for Credit Loss, Current 1.4M USD
Inventory, Net 3.25M USD -0.67%
Other Assets, Current 55K USD -50.9%
Assets, Current 6.09M USD -42.3%
Deferred Income Tax Assets, Net 27K USD -52.6%
Property, Plant and Equipment, Net 48K USD -92.7%
Operating Lease, Right-of-Use Asset 202K USD -32%
Other Assets, Noncurrent 29K USD -49.1%
Assets 6.39M USD -46.1%
Accounts Payable, Current 1.03M USD -35.7%
Employee-related Liabilities, Current 636K USD -44.7%
Accrued Liabilities, Current 1.9M USD -25%
Liabilities, Current 3.2M USD -27.3%
Deferred Income Tax Liabilities, Net 367K USD -40.3%
Operating Lease, Liability, Noncurrent 103K USD -48%
Liabilities 3.36M USD -34.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -89K USD +6.32%
Retained Earnings (Accumulated Deficit) -639M USD -1.43%
Stockholders' Equity Attributable to Parent 3.04M USD -55%
Liabilities and Equity 6.39M USD -46.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.07M USD +59.1%
Net Cash Provided by (Used in) Financing Activities 10.2M USD
Net Cash Provided by (Used in) Investing Activities -7K USD -100%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 29.4M shares +751%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.08M USD -141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.15M USD -75.3%
Deferred Tax Assets, Valuation Allowance 76.9M USD +5.42%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 77M USD +5.28%
Operating Lease, Liability 216K USD -29.6%
Depreciation 6K USD -83.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.01M USD +74.1%
Lessee, Operating Lease, Liability, to be Paid 231K USD -31.9%
Property, Plant and Equipment, Gross 150K USD -85.4%
Operating Lease, Liability, Current 113K USD +3.67%
Lessee, Operating Lease, Liability, to be Paid, Year Two 59K USD -48.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 115K USD +3.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 1K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 15K USD -53.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 59K USD
Deferred Tax Assets, Operating Loss Carryforwards 67.9M USD +7.11%
Preferred Stock, Shares Authorized 10M shares +100%
Unrecognized Tax Benefits 1.05M USD 0%
Operating Lease, Payments 27K USD -69%
Additional Paid in Capital 642M USD +0.83%
Amortization of Intangible Assets 33K USD -98.2%
Deferred Tax Assets, Net of Valuation Allowance 92K USD -48.6%
Share-based Payment Arrangement, Expense 465K USD -55.2%